Combined effect of bromelain and turmeric against acetic acid induced ulcerative colitis in wistar rats
Keywords:Disease activity index, macroscopic score, bromelain, myeloperoxidase, ulcerative colitis
Objective: The present study planned to study the combined effect of Bromelain and Turmeric in acetic acid induced ulcerative colitis in Wistar rats.
Methodology: Wistar rats of either sex (n = 30) were divided into 5 groups. Group – I, Sham control, administered single dose of vehicle rectally; Group –II, colitis control, colitis was induced by rectal administration of single dose of 2 ml of 3%, v/v of acetic acid in 0.9% saline; Group–III, treated with Turmeric (50 mg/kg/p.o); Group–IV, treated with Bromelain (100 mg/kg/p.o) and Group –V, treated with both Turmeric (50 mg/kg/p.o) and Bromelain (100 mg /kg/p.o). Colitis was induced in all the treatment groups on first day and drug treatment was continued for 7 days. During the treatment period, Disease Activity Index (DAI) was assessed daily and on 8th day White Blood Cell (WBC) Count and Differential Leucocyte Count (DLC) was performed and on 9th day all the rats were sacrificed for the assessment of intestinal inflammation, colon myeloperoxidase (MPO) levels and Histopathology. Results obtained were analysed by one-way analysis of variance followed by Tukey’s multiple comparison test.
Results: Overall changes in DAI, Inflammatory scores, WBC, DLC and MPO has shown significant improvement with Turmeric and Bromelain compared to Colitis control. However, the combined therapy has shown to be more effective in alleviating ulcerative colitis compared to individual therapies.
Conclusion: The present study recommends that the combination of Turmeric and Bromelain has synergistic effect in treating ulcerative colitis.
Langner C, Magro F, Driessen A, Ensari A, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, De Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R, Geboes K. The histopathological approach to inflammatory bowel disease: A practice guide, Springer Verlag, 2014.
Wilks S, Moxon W. Lectures on Pathological Anatomy. LANE Libr., 733 (1875).
Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: A pathologic and clinical entity. J. Am. Med. Assoc., 99, 1323–9 (1932).
Liu TC, Stappenbeck TS. Genetics and Pathogenesis of Inflammatory Bowel Disease. Annu. Rev. Pathol. Mech. Dis., 11, 127–48 (2016).
Solanki R, Madat D, Chauhan K, Parmar L. Recent approaches in pathogenesis of inflammatory bowel disease, 2010.
Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY, Wei SC. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J. Formos. Med. Assoc., 118, 1083–92 (2019).
Zhang, Yi-Zhen, and Yong-Yu Li. Inflammatory bowel disease: pathogenesis. World journal of gastroenterology: WJG 20, no. 1,91 (2014).
Baliga MS, Joseph N, Venkataranganna M V., Saxena A, Ponemone V, Fayad R. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: Preclinical and clinical observations. Food Funct., 3, 1109–17 (2012).
Ma Z, Wang N, He H, Tang X. Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application. J. Control. Release, 316, 359–80 (2019).
Chakraborty M, Bhattacharjee A, Kamath JV. Cardioprotective effect of curcumin and piperine combination against cyclophosphamide-induced cardiotoxicity. Indian J. Pharmacol., 49, 65–70 (2017).
Hale LP, Greer PK, Trinh CT, Gottfried MR. Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. Clin. Immunol., 116, 135–42 (2005).
Zhou Z, Wang L, Feng P, Yin L, Wang C, Zhi S, Dong J, Wang J, Lin Y, Chen D, Xiong Y, Peng J. Inhibition of epithelial TNF-α receptors by purified fruit bromelain ameliorates intestinal inflammation and barrier dysfunction in colitis. Front. Immunol., 8, (2017).
Thippeswamy BS, Mahendran S, Biradar MI, Raj P, Srivastava K, Badami S, Veerapur VP. Protective effect of embelin against acetic acid induced ulcerative colitis in rats. Eur. J. Pharmacol., 654, 100–5 (2011).
Kottke-Marchant K, Davis BH. Laboratory Hematology Practice. Wiley-Blackwell, (2012).
Patil NR, Rasal VP, Malabade RH. Screening of mandarin oil on indomethcin induced inflammatory bowel disease in wistar rats. Indian J. Pharm. Educ. Res., 48, 1–6 (2014).
Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J. Immunol. Res., 2019, (2019).
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, 390, 2769–78 (2017).
Tabassum N, Hamdani M, Hussain Najar I. BRITISH BIOMEDICAL BULLETIN Original Natural Treatment for Inflammatory Bowel Disease, 2013.
Hewlings S, Kalman D. Curcumin: A Review of Its Effects on Human Health. Foods, 6, 92 (2017).
Pavan R, Jain S, Shraddha, Kumar A. Properties and Therapeutic Application of Bromelain: A Review. Biotechnol. Res. Int., 2012, 1–6 (2012).
Rathnavelu V, Alitheen NB, Sohila S, Kanagesan S, Ramesh R. Potential role of bromelain in clinical and therapeutic applications (Review). Biomed. Reports, 5, 283–8 (2016).
Moeinian M, Ghasemi-Niri SF, Mozaffari S, Abdolghaffari AH, Baeeri M, Navaea-Nigjeh M, Abdollahi M. Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis. World J. Gastroenterol., 20, 10876–85 (2014).
Fabia R, Willen R, Arrajab A, Andersson R, Ahren B, Bengmark S. Acetic acid-induced colitis in the rat: A reproducible experimental model for acute ulcerative colitis. Eur. Surg. Res., 24, 211–25 (1992).
Sartor RB. Mechanisms of disease: Pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol., 3, 390–407 (2006).
Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin. Immunol., 128, 66–74 (2008).
Mouzaoui S, Rahim I, Djerdjouri B. Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-α-induced oxidative stress, colitis and hepatotoxicity in mice. Int. Immunopharmacol., 12, 302–11 (2012).
Jiang H, Deng CS, Zhang M, Xia J. Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J. Gastroenterol., 12, 3848–53 (2006).
Song WB, Wang YY, Meng FS, Zhang QH, Zeng JY, Xiao LP, Yu XP, Peng D dan, Su L, Xiao B, Zhang ZS. Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-κB activation. PLoS One, 5, (2010).
Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest. Endosc. Clin. N. Am., 24, 367–78 (2014).
How to Cite
Copyright (c) 2021 R. Padmavathi, K B Keerthana, A. Lalitha Devi, Y. Sree Hari, Abdul Samad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.